1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
Delayed Nasdaq Helsinki  -  05/25 11:29:37 am EDT
3.500 EUR    0.00%
05/24NANOFORM 1Q 2022 REPORT : Quarterly record of new projects and new customers
AQ
05/24Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Invitation to Nanoform's Interim Report January-March 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

11/17/2021 | 03:16am EDT

Press release

Nanoform Finland Plc

November 17, 2021

10:15 a.m. Finnish time / 09:15 a.m. Swedish time

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has won the Star of Innovation award at the 9th annual European Small and Mid-Cap Awards. The award win recognizes Nanoform as a listed company that places innovation at the center of its strategy for business development and introduces an innovative technology to the market. On the same night, 16th November 2021, Nanoform were also shortlisted for two further awards at the European Mediscience Awards which took place in London. This was a great accolade as many of the award winners were rightly recognized for their outstanding contribution to COVID such as AstraZeneca and BioNTech. To be in the presence of industry drug development giants shows that small continues to be powerful.

The European Small and Mid-Cap Awards, launched in 2013, were established by the European Commission to recognize selected European listed growth companies. EuropeanIssuers, who represent listed companies, and the Federation of European Securities Exchanges (FESE), who represent European stock exchanges, are co-organizers of the event.

Nanoform, listed on Nasdaq, was shortlisted out of 27 nominations from 17 countries, listed on different European stock exchanges.

Prof. Edward Hæggström, Nanoform CEO, commented: "We are honored to have received the Star of Innovation award within European Small and Mid-Cap Awards 2021. Patients' lives depend on innovation, and they are at the heart of all that we do in Nanoform. We would like to thank the European Commission, EuropeanIssuers and the Federation of European Securities Exchanges for recognizing our innovation, Nasdaq IPO, job creation and speed of growth. European capital markets are highly efficient, and we are grateful for the endorsement. In future, we look forward to continue being an important part of the European growth engine."

For further information, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information please visit http://www.nanoform.com

https://news.cision.com/nanoform/r/nanoform-wins-star-of-innovation-award-at-the-european-small-and-mid-cap-awards-2021,c3455350

https://mb.cision.com/Main/18905/3455350/1497512.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about NANOFORM FINLAND OYJ
05/24NANOFORM 1Q 2022 REPORT : Quarterly record of new projects and new customers
AQ
05/24Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/10Invitation to Nanoform's Interim Report January-March 2022
AQ
05/04Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of ..
CI
05/04Nanoform launches "STARMAP Online" placing AI-power at the fingertips of medicine devel..
AQ
04/12Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
04/12Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland P..
AQ
04/12Share subscriptions based on Nanoform Finland Plc's multiple Stock Option Programs
AQ
04/12Nanoform Finland Elects Members to Audit and Compensation Committee
CI
04/12Resolutions of Nanoform Finland Plc's Annual General Meeting on April 12, 2022
AQ
More news
Financials
Sales 2022 7,00 M 7,51 M 7,51 M
Net income 2022 -18,7 M -20,1 M -20,1 M
Net cash 2022 74,4 M 79,8 M 79,8 M
P/E ratio 2022 -14,0x
Yield 2022 -
Capitalization 274 M 293 M 294 M
EV / Sales 2022 28,5x
EV / Sales 2023 11,0x
Nbr of Employees 125
Free-Float 74,0%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,50 €
Average target price 8,88 €
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Edward Hæggström Chief Executive Officer
Albert Häggström Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Gonçalo Nuno N. da Silva Rebelo de Andrade Chief Business Operations
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-46.81%294
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494